Axel Schambach

Professor

Hannover Medical School

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Axel Schambach is a faculty member at Hannover Medical School in Germany. His research focuses on innovative therapeutic approaches for aggressive B-cell lymphomas, gene therapy enhancements, and CAR T cell technologies. Recent publications highlight his work on genotoxicity assays, targeting solid cancers, and expanding murine hematopoietic stem and progenitor cells for gene therapy. He is deeply engaged in the development of advanced immunotherapy methods and disease models.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (4)

Fabio Candotti

Full Professor of Medicine

Lausanne University Hospital

SWITZERLAND

View details

Martin Hjort

Lund University

SWEDEN

View details

Thomas Fox

University College London Hospitals NHS Foundation Trust

UNITED KINGDOM

View details

Daniel Nettersheim

Univ.-Professor

Heinrich Heine University Düsseldorf

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Axel Schambach

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Development of an <i>in vitro</i> genotoxicity assay to detect retroviral vector-induced lymphoid insertional mutants.

Targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1.

TGF<i>β</i> Inhibitor A83-01 Enhances Murine HSPC Expansion for Gene Therapy.

Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia.

CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process.

CAR-NK Cells Targeting HER1 (EGFR) Show Efficient Anti-Tumor Activity against Head and Neck Squamous Cell Carcinoma (HNSCC).

CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners.

Engineered human Diamond-Blackfan anemia disease model confirms therapeutic effects of clinically applicable lentiviral vector at single-cell resolution.

Tumor Organoid and Spheroid Models for Cervical Cancer.

Access to gene therapy for rare diseases when commercialization is not fit for purpose.

Collaborators (4)

Fabio Candotti

Martin Hjort

Thomas Fox

Daniel Nettersheim

Make your next move.